Review

HbA1c from 12 to 6.9 in just 2 months! Real Diabetes Patient Review | Sugar Control Journey #Shorts A real and …

Abstract Type 2 diabetes mellitus (T2DM) is considered a chronic, progressive and irreversible condition; however, evidence accumulated over the past decade demonstrates that remission of this disease can be achieved …

There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay …

The Cureus Journal of Medical ScienceAngiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-AnalysisType 2 diabetes mellitus (T2DM) …

IntroductionWhat are edible cacti?Blood sugar regulationEffects on cholesterol and triglyceridesGut microbiota modulationBioactive compounds beyond fiberPractical dietary considerationsResearch gaps and limitationsReferencesFurther reading From traditional nopales to modern functional foods, this evidence-based …

Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health …

CureusComparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisSodium-glucose cotransporter-2 (SGLT2) inhibitors …

Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Tzield (teplizumab-mzwv) targeting young children with stage 2 …

MedWatchUS FDA grants priority review for Sanofi’s type 1 diabetes drugFrance is seeking fast-track approval of diabetes drug Tzield in children aged over one..2 hours ago

Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the …